Imipenem/Cilastatina Aurovitas

Imipenem/cilastatin, the active ingredient in Imipenem/Cilastatin Aurovitas, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It provides broad‑spectrum coverage against Gram‑positive, Gram‑negative and anaerobic bacteria and is employed in hospitalized adults and children with serious infections.

GNH USA supplies Imipenem/Cilastatin Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable global logistics.

Imipenem/cilastatin is used for a range of severe bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides rapid bacterial eradication to resolve intra‑abdominal sepsis. - Complicated urinary tract infections: offers effective clearance of resistant uropathogens in the urinary tract. - Skin and soft‑tissue infections: eliminates causative bacteria to promote healing of deep tissue infections. - Community‑acquired and hospital‑acquired pneumonia: delivers broad‑spectrum activity to treat pulmonary infections. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis. - Febrile neutropenia: offers empiric coverage for neutropenic patients at risk of bloodstream infection.

Like all antibiotics, Imipenem/cilastatin may cause adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Rash

Serious or Rare Side Effects: - Seizures, particularly in patients with renal dysfunction or CNS disease - Anaphylactic reactions - Clostridioides difficile‑associated colitis

Careful assessment and monitoring are required when using Imipenem/cilastatin.

- Renal function assessment: evaluate creatinine clearance and adjust dose in renal impairment. - Seizure risk: monitor patients with a history of seizures or CNS disorders. - Allergy history: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Pregnancy and lactation: use only when the potential benefit justifies the potential risk to the fetus or infant. - Concomitant medications: review for drugs that may lower seizure threshold or affect renal clearance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Valproic acid: co‑administration can markedly reduce valproate levels, risking seizure breakthrough. - Probenecid: may increase imipenem concentrations and heighten nephrotoxicity. - Other carbapenems: concurrent use can lead to additive toxicity without therapeutic benefit.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance renal clearance of imipenem, requiring dose consideration. - Aminoglycosides: combined nephrotoxic potential warrants renal function monitoring. - NSAIDs: can affect renal perfusion and increase risk of renal impairment.